Radius Health (NASDAQ:RDUS) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, January 10th.
Other research analysts have also issued research reports about the stock. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Citigroup started coverage on shares of Radius Health in a research note on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price target for the company. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research note on Friday, November 3rd. Finally, Jefferies Group decreased their price target on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $48.00.
Radius Health (RDUS) traded down $0.60 during trading on Wednesday, reaching $34.10. 922,100 shares of the company traded hands, compared to its average volume of 970,020. Radius Health has a 52-week low of $24.66 and a 52-week high of $49.16. The firm has a market capitalization of $1,520.00, a PE ratio of -6.28 and a beta of 1.10. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.
In other Radius Health news, major shareholder Growth N. V. Biotech bought 50,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average cost of $26.25 per share, with a total value of $1,312,500.00. Following the acquisition, the insider now directly owns 5,698,799 shares of the company’s stock, valued at approximately $149,593,473.75. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Brent Hatzis-Schoch acquired 1,778 shares of the company’s stock in a transaction on Friday, November 10th. The stock was purchased at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the completion of the purchase, the vice president now directly owns 2,278 shares in the company, valued at approximately $63,989.02. The disclosure for this purchase can be found here. Insiders bought a total of 158,578 shares of company stock worth $4,659,916 over the last ninety days. Corporate insiders own 15.00% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in RDUS. Cubist Systematic Strategies LLC purchased a new stake in shares of Radius Health during the 3rd quarter worth $110,000. Sei Investments Co. boosted its position in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 541 shares in the last quarter. Advisor Group Inc. boosted its position in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 2,888 shares in the last quarter. Finally, Amalgamated Bank purchased a new stake in shares of Radius Health during the 2nd quarter worth $211,000.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.